Category: Mergers & Acquisitions
Boston Scientific's Lotus TAVI system minimizes leakage in an early trial, St. Jude Medical gains on a Goldman upgrade and the SEC closes a probe of Zoll's Middle East sales just ahead of $2.3B Asahi merger.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
A group of Kensey Nash shareholders sue to block the $360 million Royal DSM merger; RyMed and ICU Medical declare victory against each other; a California judge frees Lap-Band patients from forced arbitration; and hearing aid maker HearUSA confirms bankruptcy.
Kensey Nash shareholders sue to block Royal DSM merger
Interim Boston Scientific CEO Hank Kucheman stands behind the company's ill-fated Guidant buyout; also, analysts on Abbott's device/drug split: "Take the money and run"; Mako's missed quarter may be bad news for Intuitive; Amendia and Medline join forces for spine surgery; Verisante completes the beta version of its Aura skin lesion detection device; Philips Medical signs a fiber optic development deal with Luna Innovations; a free Skyscape medical app makes bank; plus GPO news, a Funding Roundup and analysts' ups and downs.
Boston Scientific's (NYSE:BSX) interim CEO Hank Kucheman still believes in the company's ill-fated acquisition of Guidant Corp., a deal worth $26 billion that was followed by recalls, lawsuits and criminal charges.
Medtronic's CRM layoffs may be a sign of a prolonged slump; Johnson & Johnson might be eyeing Edwards or St. Jude; Edwards wins CMS Medicare coverage for its Sapien TAVI system; Masimo CEO Kiani tells us why the med-tech industry should protect its young; GOP govs ask Senate and House leaders to kill the medical device tax; MassDevice.com looks at the most talked about device makers in April; and Siemens reveals probes into Russian payments and its diagnostics business.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.
U.S. breast implant makers may see an upside to the French PIP implant scandal, Kensey Nash agrees to a $360 million buyout by Royal DSM and J&J makes its 1st med-tech acquisition in China.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Johnson & Johnson acquires its 1st Chinese medical device maker; Aethlon expects $1.4M in full-year revenues; Washington group pushes women's pelvic health; Invest in R&D, survey says; plus, GPO deals, a Funding Roundup and analysts' ups and downs.
Health care giant Johnson & Johnson (NYSE:JNJ) made its 1st acquisition in China this week, picking up Guangzhou Bioseal Biotech for an undisclosed amount.
J&J has been doing business in China for more than 25 years, including last year's launch of a medical device and diagnostics innovation center there.
Kensey Nash accepts a $38.50-per-share cash buyout offer from Royal DSM worth about $360 million and reports a swing from Q3 red to black.
Kensey Nash (NSDQ:KNSY) agreed to a $38.50-per-share cash buyout offer from Royal DSM worth about $360 million, a 33% premium over KNSY's $29.01 closing price yesterday.
KNSY shares soared 32.2% in pre-market trading on the news, reaching $38.35 – 25.7% above its 52-week high of $30.50 per share, even as the company revealed a 3rd-quarter swing from red ink to black.
